Cure My Disease

Don't miss your cure!

 Log in / Sign up

Targeted pill aims to halt recurrent ovarian and endometrial cancers

NCT ID NCT04469764

Recruiting now Disease control Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This phase II trial tests the drug abemaciclib in people whose ovarian or endometrial cancer has returned and whose tumors have a specific genetic change (CDK4/6 pathway activation). Abemaciclib is a pill that blocks certain enzymes that cancer cells need to grow. The study will see if the drug can stop or slow the cancer's progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
abemaciclib, a CDK4/6 inhibitor drug taken by mouth
What this could lead to
If successful, this could provide a new targeted treatment option for patients with recurrent ovarian or endometrial cancers that have a specific genetic feature.
What could go wrong
This is an early-phase trial with only 32 participants, so results may not apply broadly. The drug may cause side effects and may not effectively control tumor growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial carcinoma endometrium neoplasm fallopian tube carcinoma fallopian tube neoplasm ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT ENDOMETRIAL CARCINOMA RECURRENT FALLOPIAN TUBE CARCINOMA RECURRENT OVARIAN CARCINOMA RECURRENT PRIMARY PERITONEAL CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UCLA / Jonsson Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90095, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.